ИНТЕРЛЕЙКИН 37 - НОВЫЙ БИОЛОГИЧЕСКИЙ МАРКЕР ПРИ КАРДИОВАСКУЛЯРНОЙ ПАТОЛОГИИ
- Авторы: Алиева А.М.1, Резник Е.В.1, Теплова Н.В.1, Аракелян Р.А.1, Шнахова Л.М.2, Байкова И.Е.1, Аккиева М.А.3, Никитин И.Г.1
-
Учреждения:
- ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
- ФГАОУ ВО «Первый московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
- ГБУЗ «Центр аллергологии и иммунологии» Минздрава Кабардино-Балкарской Республики
- Выпуск: Том 8, № 4 (2022)
- Страницы: 101-109
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2412-4036/article/view/289014
- DOI: https://doi.org/10.18565/therapy.2022.4.101-109
- ID: 289014
Цитировать
Полный текст



Аннотация
Полный текст

Об авторах
Амина Магомедовна Алиева
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Email: amisha_alieva@mail.ru
к.м.н., доцент кафедры госпитальной терапии № 2 лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Елена Владимировна Резник
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Email: elenaresnik@gmail.com
д.м.н., профессор, зав. кафедрой пропедевтики внутренних болезней лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Наталья Вадимовна Теплова
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава Россиид.м.н., профессор, заведующий кафедрой клинической фармакологии лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Роза Арамовна Аракелян
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Email: sharm@yandex.ru
студентка лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Лидия Мухамедовна Шнахова
ФГАОУ ВО «Первый московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Email: shnakhova_l_m@staff.sechenov.ru
врач 119435, г. Москва, Большая Пироговская ул., д. 4, стр. 1
Ирина Евгеньевна Байкова
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Email: 1498553@mail.ru
к.м.н., доцент кафедры госпитальной терапии № 2 лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Марьяна Анатольевна Аккиева
ГБУЗ «Центр аллергологии и иммунологии» Минздрава Кабардино-Балкарской Республики
Email: marakkieva@mail.ru
зам. главного врача по клинико-экспертной работе 360010, г. Нальчик, ул. Марко Вовчок, д. 10а
Игорь Геннадиевич Никитин
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Email: igor.nikitin.64@mail.ru
д.м.н., профессор, заведующий кафедрой госпитальной терапии № 2 лечебного факультета 117997, г. Москва, ул. Островитянова, д. 1
Список литературы
- Boorsma E., Ter Maaten J., Damman K. et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020; 17(10): 641-55. https://dx.doi.org/10.1038/s41569-020-0379-7.
- Алиева А.М., Резник Е.В., Гасанова Э.Т. с соавт. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018; 5: 333-345. https://dx.doi.org/10.20514/2226-6704-2018-8-5-333-345.
- Su Z., Tao X. Current understanding of IL-37 in human health and disease. Front Immunol. 2021; 12: 696605. https://dx.doi.org/10.3389/fimmu.2021.696605.
- Mei Y., Liu H. IL-37: An anti-inflammatory cytokine with antitumor functions. Cancer Rep (Hoboken). 2019; 2(2): e1151. https://dx.doi.org/10.1002/cnr2.1151.
- Wang L., Quan Y., Yue Y. et al.Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy. Oncol Lett. 2018; 15(4): 4711-19. https://dx.doi.org/10.3892/ol.2018.7982.
- Jia H., Liu J., Han B. Reviews of interleukin-37: Functions, receptors, and roles in diseases. Biomed Res Int. 2018; 2018: 3058640. https://dx.doi.org/10.1155/2018/3058640.
- Boraschi D., Lucchesi D., Hainzl S. et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011; 22(3): 127-47. https://dx.doi.org/10.1684/ecn.2011.0288.
- Bulau A., Nold M.F., Li S. et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci U S A. 2014; 111(7): 2650-55. https://dx.doi.org/10.1073/107pnas.1324140111.
- Supino D., Minute L., Mariancini A. et al. Negative regulation of the IL-1 system by IL-1R2 and IL-1R8: Relevance in pathophysiology and disease. Front Immunol. 2022; 13: 804641. https://dx.doi.org/10.3389/fimmu.2022.804641.
- Zhu R., Zhang F., Pan C. et al. Role of IL-37- and IL-37-treated dendritic cells in acute coronary syndrome. Oxid Med Cell Longev. 2021; 2021: 6454177. https://dx.doi.org/10.1155/2021/6454177.
- Dinarello C.A., Bufler P.Interleukin-37. Semin Immunol. 2013; 25(6): 466-68. https://dx.doi.org/10.1016/j.smim.2013.10.004.
- Chen H., Fujita M. IL-37: A new player in immune tolerance. Cytokine. 2015; 72(1): 113-14. https://dx.doi.org/10.1016/j.cyto.2014.11.025.
- Li S., Neff C., Barber K. et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015; 112(8): 2497-502. https://dx.doi.org/10.1073/pnas.1424626112.
- Sharma S., Kulk N., Nold M.F. et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol. 2008; 180(8): 5477-82. https://dx.doi.org/10.4049/jimmunol.180.8.5477.
- Patel F.J., Volkmann D.T., Taylor G.W. et al. Retracted: IL-37 reduces inflammatory response after cerebral ischemia and reperfusion injury through down-regulation of pro-inflammatory cytokines. Cytokine. 2014; 69(2): 234-39. https://dx.doi.org/10.1016/j.cyto.2014.06.011.
- Yu K., Min X., Lin Y. et al. Increased IL-37 concentrations in patients with arterial calcification. Clin Chim Acta. 2016; 461: 19-24. https://dx.doi.org/10.10167j.cca.2016.07.011.
- Wennerberg E., Spada S., Rudqvist N.P. et al. CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection. Cancer Immunol Res. 2020; 8(4): 465-78. https://dx.doi.org/10.1158/2326-6066.CIR-19-0449.
- Nold M.F., Nold-Petry C.A., Zepp J.A. et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010; 11(11): 1014-22. https://dx.doi.org/10.1038/ni.1944.
- Nold-Petry C.A., Lo C.Y., Rudloff I. et al. IL-37 requires the receptors IL-18Ra and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015; 16(4): 354-65. https://dx.doi.org/10.1038/ni.3103.
- Melillo J.A., Song L., Bhagat G. et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol. 2010; 184(5): 2638-45. https://dx.doi.org/10.4049/jimmunol.0902960.
- Wang N., Liang H., Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front Immunol. 2014; 5: 614. https://dx.doi.org/10.3389/fimmu.2014.00614.
- Heindl M., Handel N., Ngeow J. et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 2012; 142(5): 1093-96e6. https://dx.doi.org/10.1053/j.gastro.2012.01.011.
- Zhu Y., Qin H., Ye K. et al. Dual role of IL-37 in the progression of tumors. Cytokine. 2022; 150: 155760. https://dx.doi.org/10.1016/j.cyto.2021.155760.
- Lunding L., Webering S., Vock C. et al. IL-37 requires IL-18Ra and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015; 70(4): 366-73. https://dx.doi.org/10.1111/all.12566.
- Moretti S., Bozza S., Oikonomou V. et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014; 10(11): e1004462. https://dx.doi.org/10.1371/journal.ppat.1004462.
- Henry C., Casas-Selves M., Kim J. et al. Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. J Clin Invest. 2015; 125(12): 4666-80. https://dx.doi.org/10.1172/JCI83024.
- Bulau A., Fink M., Maucksch C. et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. Sci World J. 2011; 11: 2480-90. https://dx.doi.org/10.1100/2011/968479.
- Davis C., Zielinski M., Dunbrasky D. et al.Interleukin 37 expression in mice alters sleep responses to inflammatory agents and influenza virus infection. Neurobiol Sleep Circadian Rhythm. 2017; 3: 1-9. https://dx.doi.org/10.1016/j.nbscr.2016.11.005.
- Cavalli G., Dinarello C.A. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018; 281(1): 179-90. https://dx.doi.org/10.1111/imr.12605.
- Yousif N.G., Li J., Yousif F. et al. Expression of IL-37 in mouse protects the myocardium against ischemic injury via modulation of NF-kB activation. Circulation. 2011; 124(Suppl 21): A8603.
- Coll-Miro M., Francos-Quijorna I., Santos-Nogueira E. et al. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2016; 113(5): 1411-16. https://dx.doi.org/10.1073/pnas.1523212113.
- Yang Y., Zhang Z.X., Lian D. et al. IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int. 2015; 87(2): 396-408. https://dx.doi.org/10.1038/ki.2014.295.
- Ballak D.B., van Diepen J.A., Moschen A.R. et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014; 5: 4711. https://dx.doi.org/10.1038/ncomms5711.
- Ballak D., Li S., Johnson L.C. et al. Therapeutic oprions for interleukin-37 in metabolic and inflamm-aging diseases. Gerontologist. 2015; 55(suppl 2): 62.
- Luo Y., Cai X., Liu S. et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014; 111(42): 15178-83. https://dx.doi.org/10.1073/pnas.1416714111.
- Shuai X., Wei-min L., Tong Y.L. et al. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Sci Rep. 2015; 5: 14478. https://dx.doi.org/10.1038/srep14478.
- 3 Alagbe A., Domingos I., Adekile A. et al. Anti-inflammatory cytokines in sickle cell disease. Mol Biol Rep. 2022; 49(3): 2433-42. https://dx.doi.org/10.1007/s11033-021-07009-1.
- Chai M., Ji Q., Zhang H. et al. The protective effect of interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein E-deficient mice with diabetes. J Interferon Cytokine Res. 2015; 35(7): 530-39. https://dx.doi.org/10.1089/jir.2014.0212.
- Xu D., Wang A., Jiang F. et al. Effects of interleukin-37 on cardiac function after myocardial infarction in mice.Int J Clin Exp Pathol. 2015; 8:5247-51.
- Li J., Zhai Y., Ao L. et al.Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice. Cytokine. 2017; 95: 55-63. https://dx.doi.org/10.1016/j.cyto.2017.02.008.
- Wu B., Meng K., Ji Q. et al.Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014; 176(3): 438-51. https://dx.doi.org/10.1111/cei.12284.
- Wang X., Cai X., Chen L. et al. The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI. Mediators Inflamm. 2015; 2015: 6. https://dx.doi.org/10.1155/2015/626934.626934.
- Ji Q., Zeng Q., Huang Y. et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014; 2014: 9. https://dx.doi.org/10.1155/2014/165742.165742.
- Liu C., Cui Y., Zhang D. et al. Analysis of serum interleukin-37 level and prognosis in patients with ACS.Comput Math Methods Med. 2021; 2021: 3755458. https://dx.doi.org/10.1155/2021/3755458.
- Liu K., Tang Q., Zhu X., Yang X. IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction. Clin Chim Acta. 2017; 468: 140-44. https://dx.doi.org/10.1016/j.cca.2017.02.017.
- Yang T., Fang F., Chen Y. et al. Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation. Oncotarget. 2017; 8(6): 9686-95. https://dx.doi.org/10.18632/oncotarget.14195.
- Ye J., Wang Y., Wang Z. et al. Circulating IL-37 levels are elevated in patients with hypertension. Exp Ther Med. 2021; 21(6): 558. https://dx.doi.org/10.3892/etm.2021.9990.
- Shou X., Lin J., Xie C. et al. Plasma IL-37 elevated in patients with chronic heart failure and predicted major adverse cardiac events: A 1-year follow-up study. Dis Markers. 2017; 2017: 9134079. https://dx.doi.org/10.1155/2017/9134079.
- Mayoux M., Roller A., Pulko V. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020; 12(534): eaav7431. https://dx.doi.org/10.1126/scitranslmed. aav7431.
- Wculek S.K., Cueto F.J., Mujal A.M. et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020; 20(1): 7-24. https://dx.doi.org/10.1038/s41577-019-0210-z.
- Cifuentes-Rius A., Desai A., Yuen D. et al. Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat Nanotechnol. 2021; 16(1): 37-46. https://dx.doi.org/10.1038/s41565-020-00810-2.
- Castenmiller C., Keumatio-Doungtsop B.C., van Ree R. et al. Tolerogenic immunotherapy: Targeting DC surface receptors to induce antigen-specific tolerance. Front Immunol. 2021; 12: 643240. https://dx.doi.org/10.3389/fimmu.2021.643240.
- Lanzavecchia A., Sallusto F. The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics. Curr Opin Immunol. 2001; 13(3): 291-98. https://dx.doi.org/10.1016/s0952-7915(00)00218-1.
- Jauregui-Amezaga A., Cabezon R., Ramirez-Morros A. et al.Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease: A phase I study. J Crohns Colitis. 2015; 9(12): 1071-78. https://dx.doi.org/10.1093/ecco-jcc/jjv144.
- Bell G., Anderson A., Diboll J. et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017; 76(1): 227-34. https://dx.doi.org/10.1136/annrheumdis-2015-208456.
- Zhu R., Sun H., Yu K. et al.Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin I ameliorate cardiac remodeling after myocardial infarction. J Am Heart Assoc. 2016; 5(12): e004406. https://dx.doi.org/10.1161/JAHA.116.004406.
- Mao X., Zhu R., Zhang F. et al. IL-37 plays a beneficial role in patients with acute coronary syndrome. Mediators Inflamm. 2019; 2019: 9515346. https://dx.doi.org/10.1155/2019/9515346.
- Шиловский И.П., Дынева М.Е., Курбачева О.М. c соавт. Роль интерлейкина-37 в патогенезе аллергических заболеваний. ACTA NATURAE. 2019; 4: 54-64. https://dx.doi.org/10.32607/20758251-2019-11-4-54-64.
- Yang Z., Kang L., Wang Y. et al. Role of IL-37 in cardiovascular disease inflammation. Can J Cardiol. 2019; 35(7): 923-30. https://dx.doi.org/10.1016/j.cjca.2019.04.007.
Дополнительные файлы
